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Abstract 
Sublingual immunotherapy (SLIT) is an effective and well-tolerated method of treating allergic respiratory diseases 
associated with seasonal and perennial allergens. In contrast to the subcutaneous route, SLIT requires a much greater 
amount of antigen to achieve a clinical effect. Many studies have shown that SLIT involves a dose–response rela-
tionship, and therefore it is important to use a proven clinically effective dose from the onset of treatment, because 
low doses are ineffective and very high doses may increase the risk of side effects. A well-defined standardization of 
allergen content is also crucial to ensure consistent quality, potency and appropriate immunomodulatory action of 
the SLIT product. Several methods of measuring antigenicity are used by manufacturers of SLIT products, including 
the index of reactivity (IR), standardized quality tablet unit, and bioequivalent allergy unit. A large body of evidence 
has established the 300 IR dose of SLIT as offering optimal efficacy and tolerability for allergic rhinitis due to grass and 
birch pollen and HDM, and HDM-induced moderate, persistent allergic asthma. The 300 IR dose also offers consist-
ency of dosing across a variety of different allergens, and is associated with higher rates of adherence and patient 
satisfaction. Studies in patients with grass pollen allergies showed that the 300 IR dose has a rapid onset of action, 
is effective in both adults and children in the short term and, when administered pre-coseasonally in the long term, 
and maintains the clinical benefit, even after cessation of treatment. In patients with HDM-associated AR and/or 
asthma, the 300 IR dose also demonstrated significant improvements in symptoms and quality of life, and significantly 
decreased use of symptomatic medication. The 300 IR dose is well tolerated, with adverse events generally being of 
mild or moderate severity, declining in frequency and severity over time and in the subsequent courses. We discuss 
herein the most important factors that affect the selection of the optimal dose of SLIT with natural allergens, and 
review the rationale and evidence supporting the use of the 300 IR dose.
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Background
Allergic rhinitis (AR) is one of the most common chronic 
conditions worldwide, affecting an estimated 500 million 
people [1]. The recommended approach to the manage-
ment of AR is a combination of patient education (with 
specific allergen avoidance when feasible), symptomatic 
pharmacotherapy and allergen immunotherapy (AIT) 
[2–4]. The goals of AR treatment are short-term sympto-
matic relief, improvement in quality of life (QoL), and of 
the modification of the immune response of the allergic 
disease [5].
Allergen immunotherapy is based on the repeated 
administration of extracts of the symptom-eliciting aller-
gens, with the aim of reducing the clinical and immu-
nological response to these allergens and, ultimately, 
inducing a persistent immunological tolerance [6, 7]. AIT 
is effective in improving symptoms, reducing the use of 
symptomatic drugs, and is the only disease-modifying 




*Correspondence:  pascal.demoly@inserm.fr 
1 Allergy Division, Pulmonology Department, Hôpital Arnaud de 
Villeneuve, University Hospital of Montpellier, Montpellier, France
Full list of author information is available at the end of the article
Page 2 of 17Demoly et al. Clin Transl Allergy  (2015) 5:44 
The most currently approved routes of AIT administra-
tion are subcutaneous immunotherapy (SCIT), involv-
ing monthly injections, and sublingual immunotherapy 
(SLIT), involving a daily dosing. Both are given over a 
period of 3–5  years. Both routes consistently demon-
strated efficacy in reducing allergic symptoms and symp-
tomatic drug use [8]. SCIT requires monthly doctors’ 
visits, but not daily dosing. SLIT can be self-administered 
at home following the initial dose, and is generally con-
sidered to have a better safety profile than SCIT [9, 10]. 
A key difference between the two routes of administra-
tion is that SLIT requires (on average) at least 50–100 
times more allergen than SCIT to elicit a similar level of 
efficacy [9] and consequently, low-dose SLIT is generally 
ineffective [11].
Sublingual immunotherapy delivery systems include 
tablets and aqueous or glycerinated liquid allergen 
extracts (‘SLIT drops’) [9]. In the former system, a rap-
idly dissolving tablet is placed under the tongue and the 
contents then swallowed once dissolved, while in the lat-
ter, an aqueous allergen extract is administered as drops, 
which are held under the tongue for a few minutes and 
then swallowed, or in some cases, spat out, but this latter 
modality has been progressively abandoned [9].
The SLIT maintenance dose, typically corresponds 
to the pre-specified maximum treatment dose or the 
maximum tolerated dose for any patient with respira-
tory allergies [12], and there is a relationship between 
the maintenance dose of allergen, the clinical efficacy, the 
administration regimen, and the adherence [13].
A convincing body of evidence has shown that SLIT 
involves a dose–response relationship [14], and it is 
important to use a proven clinically effective dose. Stud-
ies using 5-grass pollen or house dust mite (HDM) tab-
lets [15, 16] or grass pollen, birch pollen or HDM drops 
[17–19] for the treatment of respiratory allergies have 
confirmed that the daily 300 index of reactivity (IR) dose 
offers optimal efficacy and tolerability.
Here, we review the factors to consider when selecting 
the optimal dose of SLIT with natural allergens, and the 
rationale and supporting evidence for the use of the 300 
IR dose for SLIT tablets and drops.
Choosing the optimal dose of SLIT: what factors 
should be considered?
How is allergen extract potency measured?
There is considerable variability in how allergen extract 
potency is measured and reported worldwide [8, 20], and 
manufacturers use a variety of different units of meas-
urement [10]. This makes it difficult to compare studies. 
In Europe, allergen extract potency is reported in units 
based on an in-house reference, with some European 
product manufacturers using reference standards based 
on titrated skin testing of allergic patients. Biological 
potency can vary between different allergen preparations 
that are rated as having the same allergenicity.
Two SLIT therapies are currently licensed in both the 
EU and the US: Oralair® (OA) (Stallergenes, Antony, 
France) and Grazax™/Grastek® (GRA) (ALK-Abello, 
Hørsholm, Denmark/Merck, Kenilworth, NJ, USA). Stal-
lergenes applies IR to assess allergenicity, in which an 
allergen extract contains 100  IR/mL when it induces a 
wheal diameter of 7 mm in 30 patients sensitized to this 
allergen (geometric mean) on a skin prick-test [21]. All 
Stallergenes SLIT drop (Staloral®), tablet, and diagnos-
tics preparations are standardized in IR (Fig. 1) and pro-
duced using the same active pharmaceutical ingredients, 
and the same allergen source and technique. ALK-Abellò 
uses IR as a measure of allergenicity (formerly Allerbio 
SA, Varennes-en-Argonne, France) for its SLIT drop 
products (Osiris® marketed in France and also known as 
SLIT One® ULTRA in other countries but expressed in 
SRU, Standard Reactivity Unit), but the wheal diameter 
corresponding to 100 IR is 6 mm, instead of 7 mm [20]. 
ALK-Abello/Merck also uses the standardized quality 
tablet unit (SQ-T) as a measure of allergenicity. GRA is 
a 75,000 SQ-T oral lyophilizate tablet for SLIT contain-
ing a 1-grass-pollen allergen extract from timothy grass 
(Phleum pratense).
There have been attempts to standardize measures 
of allergen extract potency. In the development of 
SLIT for grass pollen allergy, the bioequivalent allergy 
unit (BAU) is a unit of standardization used for aller-
gen extracts. This is recognized and performed by the 
US Food and Drug Administration, and is based on 
the reaction to an intradermal test in highly allergic 
patients [20]. Using the BAU, OA (EXPAND) has over 
three-times more allergenicity than GRA (9000 vs 2800 
BAU, respectively). Based on the manufacturers’ in-
house assays, the major allergen content is 25  μg for 
OA and 15  μg for GRA. Limited information (such as 
assay type, reference materials, antibodies and proto-
cols) is publicly available. A comparison of the potency 
of different AIT products using these last figures is not 
feasible [14].
Administration regimens for AIT
AIT regimens can be classified as continuous (i.e. year-
round) or discontinuous. These latter may be preseasonal 
only, coseasonal only, or precoseasonal. Precoseasonal 
discontinuous regimens are typically used for SLIT and 
have efficacy and safety comparable to perennial (year-
round) regimens, while also offering economic benefits 
and improved adherence [13, 22, 23].
There are likely relationships between the adminis-
tration regimen, the maintenance dose of allergen, and 
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clinical efficacy [13]. A sufficient cumulative dose of aller-
gen may also be important, but is it the daily unit dose or 
the cumulative dose which matters the most? The EMA 
guideline on the clinical development of products for 
AIT for the treatment of allergic diseases requires stud-
ies to be performed to establish a dose–response, after 
establishing a tolerated dose range [25].
A review of the available data on dose–response rela-
tionships was conducted in 2011 by the Task Force of the 
European Academy of Allergy and Clinical Immunol-
ogy Immunotherapy Interest Group [14]. Fifteen dose-
ranging studies fulfilled their criteria for inclusion; 12 
reported a dose–response relationship for clinical effi-
cacy, and several studies also reported a dose–response 
relationship for immunological and safety endpoints. 
However, due to the use of different reference materials 
and methodologies for the determination of allergen con-
tent, variations in study design, and choice of endpoints, 
no comparisons could be made between these studies 
[14].
The approved titration of OA varies with country and/
or patient age, but typically involves a 3-day dose-escala-
tion from 100 to 300 IR per day, after which a 300 IR tab-
let is used daily as the maintenance dose until the end of 
the pollen season [26], which is adequate to ensure clini-
cal efficacy.
Need for better quality and standardization of allergen 
products
Sublingual immunotherapy products should meet the 
following requirements: be composed of high-quality 
allergen materials; have a standardized quantity of aller-
gen content, and provide clinical efficacy and safety [24]. 
Standardization is used to account for the natural vari-
ability that is evident in the biological source materials 
used to make SLIT products and the large differences 
that can exist in the protein composition and allergen 
content of the marketed products [10, 14], because these 
variations may affect the quality, potency and extent of 
immunomodulation of the SLIT drug [27]. Standardiza-
tion of the dosage is also crucial, as low doses are inef-
fective and very high doses may lead to adverse reactions 
[28].
Sublingual immunotherapy potency may be decreased 
by storage temperature, contamination (which acceler-
ates degradation of the extract), the effects of dilution 
when extracts are mixed (loss of potency is proportional 
to the extract’s dilution), type of allergen, diluents used, 
and preservatives added [28].
Standardization of allergen products is achieved by 
adjusting the potency (total allergenic activity) of the 
source material during manufacturing of the allergen 
product, to ensure batch-to-batch reproducibility [29, 30].
Fig. 1 Defining a standardized dose using the index of reactivity. An allergen extract termed the IHRP is said to have a concentration of 100 IR/
mL when, during skin prick-testing using a Stallerpoint® needle on 30 subjects who are sensitized to the corresponding allergen source, it triggers 
a wheal size of 7 mm (geometric mean). Codeine phosphate or histamine serve as positive controls (C+), and diluent only is used as a negative 
control (C−) and to assess any background effects unrelated to the allergen extract. IHRP in-house reference preparation; IR, index of reactivity
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It has been suggested that mixing multiple allergens in 
a single vaccine may dilute the allergen’s final content and 
lead to a suboptimal therapeutic effect, because clinical 
efficacy is dose-dependent [28]. However, studies investi-
gating this are lacking.
Choice of low‑dose versus high‑dose SLIT
Sublingual immunotherapy requires at least 50–100 
times more allergen than SCIT to achieve a similar level 
of clinical efficacy. An analysis of dose–response studies 
in AR has been conducted by the European Academy of 
Allergy and Clinical Immunology Immunotherapy Inter-
est Group task force on dose effect. This found that, for 
grass pollen, low doses of allergen (e.g. 5–7 µg Phl p 5 per 
day) are ineffective, and daily doses of 15–25  µg of the 
major allergen protein have been demonstrated for sig-
nificant clinical improvement, as measured by symptom 
scores with a different administration protocol [11].
The efficacy of SLIT is dose-dependent [10, 14, 24], as 
shown by both clinical and immunological endpoints in 
well-designed, adequately powered, randomized con-
trolled trials [14]. This again highlights the importance of 
administering a clinically effective dose from the onset of 
treatment.
Efficacy of 300 IR SLIT
A number of well-designed randomized controlled trials 
have consistently established 300 IR SLIT once-daily as 
the optimally safe and effective dose for AR due to grass 
pollen, HDM and birch pollen, and HDM-induced mod-
erate, persistent allergic asthma (Table 1).
SLIT tablets
Five‑grass pollen tablet
The appropriateness and effectiveness of the 300 IR 
dose for the treatment of grass pollen-associated allergy 
has been extensively characterized. In a randomized, 
double-blind, placebo-controlled (DBPC), dose-ranging 
study, adults with grass pollen-induced allergic rhino-
conjunctivitis (ARC) received either 100  IR, 300 IR or 
500 IR doses of 5-grass pollen tablet or placebo, initiated 
4 months before the estimated pollen season and contin-
ued throughout the season [16]. The 100 IR dose was not 
significantly different from placebo. In contrast, the 300 
IR dose was effective from the first pollen season [16], 
and it provided excellent efficacy with a favorable risk–
benefit profile [15, 16, 31, 32]. A dose response was not 
demonstrated between the 300 IR and 500 IR SLIT tablet 
formulations, and they showed comparable efficacy dur-
ing the peak pollen season [16, 33].
The short-term efficacy of the 300 IR dose, initiated 
either 2 or 4 months before the estimated pollen season 
and continued throughout the season, was subsequently 
confirmed in two studies in adults [34] and children [35], 
respectively. In the former, adults achieved a significant 
reduction in least squares mean Daily Combined Score 
(DCS) with 300 IR 5-grass pollen tablet treatment, com-
pared with placebo (p  <  0.001), irrespective of sensiti-
zation status or the presence of mild comorbid asthma 
[34]. In the latter, children and adolescents with con-
firmed grass pollen-associated ARC for at least 2  years 
(N = 278) had a significantly decreased Average Rhino-
conjunctivitis Total Symptom Score (ARTSS) after 300 IR 
5-grass pollen tablet treatment, compared with placebo 
[35]. Again, the presence of comorbid mild asthma or 
sensitization status had no significant effect on the effi-
cacy findings [35].
The long-term efficacy of the 300 IR dose, adminis-
tered discontinuously as a pre- and coseasonal treatment 
(with a treatment-free period for the other months of the 
year, starting after the season ends), has also been dem-
onstrated. In a randomized, DBPC, parallel-group field 
study in patients with grass pollen-induced ARC, a statis-
tically significant difference in mean DCS versus placebo 
was observed in patients using the 300 IR 5-grass pol-
len tablet over 3 years of treatment, beginning 4 months 
prior to the estimated start of the grass pollen season 
until season’s end. This treatment effect was prolonged 
for up to 2 years post-treatment [36].
The 300 IR dose shows a rapid onset of action. In a ran-
domized, DBPC, parallel-group allergen-challenge cham-
ber study in patients with grass pollen-induced ARC, 
after 1 week of treatment, a difference in ARTSS was evi-
dent between 300 IR 5-grass pollen tablet and placebo. 
After 1  month of treatment, this improvement was sig-
nificantly higher for the 300 IR dose versus placebo and 
was maintained over the following months [37].
Taken together, these studies in patients with grass pol-
len-induced ARC demonstrate that the 300 IR dose has 
a rapid onset of action and is effective in both adults and 
children over the short term, and when administered dis-
continuously over the long term, and is associated with a 
prolonged benefit, even after cessation of treatment.
House dust mite tablet
Two randomized, DBPC, pivotal studies have demon-
strated the efficacy of the 300 IR SLIT tablet for HDM-
induced AR.
The first study was conducted over 2  years in adults 
with confirmed HDM-associated AR (with or without 
intermittent asthma) who received either a 300 IR or 500 
IR dose of HDM tablet or placebo daily for 12  months, 
and were then followed up during the subsequent treat-
ment-free year [15]. In the first year, patients in the 300 
IR group experienced a significant reduction in mean 
Average Adjusted Symptom Score (AAdSS), compared 
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with those receiving placebo. This efficacy was main-
tained during the following treatment-free year, with 
these patients having significantly lower AAdSS ver-
sus placebo [15]. Patients who received the 300 IR dose 
also had a lower ARTSS in years 1 and 2, respectively, 
than those who received placebo. A significant overall 
improvement was demonstrated in the Rhinoconjunctivi-
tis Quality of Life Questionnaire (RQLQ) score in the 300 
IR group versus the placebo group in the first year, and at 
the end of treatment, the proportion of patients report-
ing marked improvement in symptoms was higher in 
the 300 IR group than in the placebo group, with greater 
treatment success [15].
The second, large-scale study was conducted in Japa-
nese adults with confirmed HDM-associated AR (with 
or without intermittent asthma), who received either a 
300 IR or 500 IR dose of HDM tablet or placebo daily for 
12 months [38]. Patients receiving the 300 IR dose had a 
significant lower AAdSS, and a significant lower ARTSS, 
in the last 2 months of treatment, compared with their 
counterparts receiving placebo. This was accompanied 
by significant improvements in QoL, and by end of treat-
ment, a marked improvement in symptoms, compared 
to the placebo group. In the subset of adolescents, those 
receiving the 300 IR dose also had a statistically signifi-
cant lower AAdSS than those receiving placebo [38].
SLIT drops
The 300 IR SLIT drop preparations (Staloral®) are indi-
cated in IgE-mediated respiratory allergic diseases, 
mainly involving rhinitis, conjunctivitis, rhinoconjuncti-
vitis or asthma (mild to moderate) of a seasonal or peren-
nial nature.
Five‑grass pollen drops
The material to produce tablets and drops is exactly the 
same. Like the 5-grass pollen tablet, a long-term effect 
has been shown for 5-grass pollen drops. A randomized, 
DBPC study in patients with grass pollen-induced AR 
evaluated the efficacy, carry-over effect and safety of 
coseasonal treatment with 5-grass pollen drops using 
ultra-rush titration with increasing doses up to 300 IR 
[17]. Treatment consisting of a daily intake of a 300 IR 
tablet throughout the season was effective from the first 
season onwards, with increasing efficacy observed over 
3 years of treatment. There was a trend for a carry-over 
effect of seasonal SLIT (low pollen exposure in follow-up 
year) [17].
Birch pollen drops
A large, randomized, DBPC study in patients with birch 
pollen-induced ARC evaluated the efficacy and safety 
of treatment with 300 IR birch pollen drops, beginning 
4  months before the estimated pollen season start and 
continuing until season’s end [19]. Pre- and coseasonal 
treatment with 300 IR birch pollen drops demonstrated 
sustained efficacy over 2  consecutive pollen seasons. 
Over the first and second birch pollen periods, a signifi-
cant decrease in least squares means AAdSS versus pla-
cebo was noted in the 300 IR group. The least squares 
mean Average Rescue Medication Score (ARMS) versus 
placebo over the first and second pollen seasons was 
also significantly decreased with 300  IR birch pollen 
drops therapy [19]. This was accompanied by significant 
improvements in RQLQ score over both periods, respec-
tively, compared with placebo [19].
House dust mite drops
A randomized, DBPC study investigated the efficacy 
and safety of daily 300 IR HDM drops over 12  months 
in Chinese adults with mild to moderate, persistent 
HDM-induced asthma [18]. The primary endpoint was 
well-controlled asthma (Global Initiative for Asthma 
classification) for ≥16 of the last 20 weeks of treatment, 
with total control of asthma being a secondary criterion. 
In a subgroup analysis, significant clinical benefits ver-
sus placebo were achieved with 300 IR HDM drops in 
patients with moderate, persistent asthma (>400–800 µg 
budesonide per day), but not mild asthma, at baseline. 
In the former group, there was a greater achievement 
of well-controlled asthma and totally controlled asthma, 
and a greater mean reduction in inhaled corticosteroid 
use [18]. A retrospective, observational study found that 
children with HDM-associated AR (N =  78) showed a 
significant improvement in asthma symptoms, and a 
reduction in asthma medication use, following 300 IR 
HDM tablet treatment [39].
Tolerability and safety of 300 IR SLIT
Currently, 300 IR SLIT preparations contain natural aller-
gens, but the limited contact with effector cells results in 
much reduced systemic reactions, compared with SCIT 
[28].
The incidence of adverse events (AEs) with SLIT does 
not appear to be dose-dependent, unlike SCIT, where 
increased frequencies of AEs are associated with higher 
allergen doses [14].
Safety has been evaluated in SLIT doses up to 1125 
times greater than those used for SCIT [21]. Studies 
using 5-grass pollen or HDM tablets [15, 16] or grass 
pollen, birch pollen or HDM drops for the treatment of 
AR/ARC [17, 19] or HDM-induced mild to moderate, 
persistent asthma [18] have confirmed that the 300 IR 
per day dose offers optimal tolerability. The 300 IR dose 
of SLIT was well tolerated in children, adolescents and 
adults, even when administered as coseasonal treatment 
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and even with ultra-rush titration schemes in SLIT drops 
[40]. The most frequently reported AEs were application-
site reactions, and there was no report of anaphylactic 
shock. Rates of treatment-emergent AEs (TEAEs) were 
generally comparable between 300 IR SLIT and placebo 
for SLIT solutions and 5-grass pollen tablet, and serious 
AEs were rare [41, 42]; for the 300 IR HDM tablet, AE 
incidence was higher than in the placebo group. In clini-
cal trials of the 5-grass pollen tablet, at least one TEAE 
was reported in 76.9 % of patients receiving active treat-
ment and in 69.8 % of placebo-treated patients [41]. AEs 
are generally mild or moderate in severity, and rarely lead 
to treatment discontinuation. Furthermore, AEs tend 
to decline in frequency and severity over time and with 
repeated treatment [41]. In a study in 94 adult asthmat-
ics exposed to doses of HDM tablet up to 2000 IR, there 
were no reports of anaphylaxis nor use of epinephrine, 
and no serious AEs [43].
Long-term studies have shown that when adminis-
tered over consecutive seasons, the frequency of AEs 
decreased over each consecutive year of treatment with 
5-grass pollen tablets or drops [17, 40, 41].
A large observational study in children and adoles-
cents with AR due to grass or tree (birch, alder, hazel) 
pollen for ≥1 year (with or without intermittent asthma) 
demonstrated the favorable safety and tolerability of an 
ultra-rush, high-dose SLIT drops regimen reaching a 
maintenance dose of 300 IR within 90  min [44]. Treat-
ment was initiated with a sublingual application of 30 IR 
SLIT, followed by 3 applications of increasing dosage at 
30-min intervals (30-90-150-300 IR regimen). The subse-
quent maintenance phase at 300 IR (or highest tolerated 
dose) lasted up to 4 months, depending on length of pol-
len season. During ultra-rush titration, predominantly 
mild and local AEs occurred, which resolved within 
150  min. During the maintenance phase, of the AEs 
reported, the most frequent local events were oral pru-
ritus, burning sensation, lip or tongue swelling, and gas-
trointestinal symptoms, and the most frequent systemic 
events were rhinoconjunctivitis and asthma. A single 
clinically significant asthma event occurred in a boy aged 
11  years with known asthma (dysphagia and dyspnea 
on day 4, immediately after the 300 IR dose). Symptoms 
resolved with prednisone, clemastine and theophylline 
treatment, and after 4 days, SLIT was resumed with grad-
ually increasing doses to 300 IR [44].
In a Spanish study, SLIT drops have also demonstrated 
a favorable safety profile when administered by non-con-
ventional, ultra-rush dosing regimens using SLIT extracts 
standardized in IR/mL (Staloral 300 Rapid®). This pro-
spective, observational, multicenter study evaluated the 
tolerability of SLIT drops administered as an ultra-rush 
300 IR dose to children with a respiratory allergic disease 
(AR, ARC and/or bronchial asthma) induced by HDM, 
grasses or olive trees, but with no prior history of AIT 
[45]. Treatment was initiated with 2 sublingual applica-
tions of ultra-rush 300 IR SLIT, followed by 3 applica-
tions at 30-min intervals. The subsequent maintenance 
dosing regimen was 5 once-daily 300 IR sublingual appli-
cations. In this study, ultra-rush 300 IR SLIT appeared to 
be better tolerated than the conventional dosing regimen 
in this pediatric population, which may facilitate adher-
ence and eliminate the need for dose escalation [45].
Adherence and patient satisfaction
A large, retrospective, multicenter, observational study 
of HDM drops, in which patients were titrated to a 
maintenance dose of 300 IR daily, evaluated physician 
perception of patient satisfaction and compliance with 
treatment. It was shown that both adult and pediatric 
patients with AR (with or without asthma) were highly 
satisfied and adhered to their treatment [46, 47]. Simi-
larly, satisfaction rates were high in a multicenter, obser-
vational, cross-sectional study carried out in Spain in 
patients with grass pollen-induced ARC who were pre-
viously naïve to 300 IR 5-grass pollen tablet therapy. A 
safe, shorter initial-treatment scheme was used, in which 
titration to the 300 IR daily dose was reached over 5 days. 
This shorter conventional scheme with reduced titration 
period may improve the patient’s adherence to treatment 
[48–50]. However, persistence on therapy after the first 
dose still seems to be low [51].
Summary and discussion
AIT is the only disease-modifying intervention avail-
able for the treatment of allergy [6, 7]. For a successful 
AIT, the chosen product should be of high quality, with 
a proven, sustained, documented and validated effective 
dose. Studies of SLIT have focused on defining the opti-
mal dose of major allergen, and the administration fre-
quency, duration of treatment, and number of treatment 
seasons [13].
Low-dose SLIT is generally ineffective, whereas high-
dose SLIT has been demonstrated to be clinically effec-
tive and safe. For grass pollen, daily doses of 15–25 µg of 
the major allergen protein are typically required for sig-
nificant clinical improvement [11].
There is substantial evidence demonstrating a dose–
response relationship in SLIT. Studies using SLIT tablets 
[15, 16] or drops [17–19] for the treatment of AR/ARC 
and/or moderate, persistent asthma have confirmed that 
the 300 IR per day dose offers optimal efficacy and toler-
ability. The 300 IR dose is also appropriate and provides 
effective treatment for a variety of different allergens, 
offering simplicity of dosing, which may not be the 
case for other allergen preparations that use alternative 
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measures of potency, depending on the allergen. 300 IR 
SLIT shows a favorable efficacy profile, reducing allergy-
related symptoms associated with HDM or pollen, and 
decreasing the use of symptomatic rescue medications 
and asthma medication, sensitization status and/or the 
presence of mild asthma. In studies of SLIT that used 
AEs as a clinical endpoint, dose-dependent increases in 
efficacy were not associated with an increased frequency 
of AEs, which possibly reflects the different sites of action 
within the immune system.
The improved safety profile of SLIT compared with 
SCIT is probably due to the fact that oral antigen-pre-
senting cells exhibit a tolerogenic phenotype, which 
reduces the induction of pro-inflammatory immune 
responses that lead to systemic allergic reactions [9]. 
Most side effects with 300 IR SLIT are mild to moder-
ate local reactions involving the oral or gastrointestinal 
mucosa. If not adequately managed, these can lead to 
treatment discontinuation. Effective management allows 
patients to reach the maintenance dose with no further 
reactions [52].
The conventional dosing scheme for 300 IR SLIT drops 
(Staloral®) consists of two phases: a titration phase with 
an escalation of the dose and a maintenance phase with 
a stable dose. In this conventional scheme, the titra-
tion phase lasts for up to 10  days, with a possible dose 
increase from 10 IR to 300 IR [42]. Results from an analy-
sis of clinical data collected from 640 patients treated 
using an ultra-rush one-day SLIT titration phase, with a 
dose increase from 30 IR to 240 IR or 300 IR, were simi-
lar to those observed using a titration phase over 12 days. 
However, it is important to note that the ultra-rush regi-
men should only be used in a hospital setting, under the 
close supervision of the prescribing physician.
300 IR SLIT is associated with high rates of adherence 
and satisfaction, demonstrating that this dose is accept-
able to patients. This is likely due to the favorable clinical 
efficacy and tolerability profile as well as the convenience 
of 300 IR SLIT, which allows at-home administration in 
adults, adolescents and children. Further research would 
be valuable to investigate adherence rates of patients 
using 300  IR SLIT over successive pollen seasons, and 
improvement in QoL. “Increasing the effectiveness of 
adherence interventions may have a far greater impact 
on the health of the population than any improvement in 
specific medical treatments” [53].
Conclusions
Successful AIT requires the use of high-quality prod-
ucts with a proven effective, standardized dose and 
biological potency. The dose is a key success factor and 
should be clearly defined. A robust body of clinical evi-
dence pertaining to different allergens for AR and/or 
HDM-induced moderate, persistent asthma has estab-
lished the 300 IR per day dose as offering optimal efficacy 
and safety in different modes of administration (tablets 
and drops). The 300 IR per day dose has also been shown 
to promote patient adherence to SLIT therapy, com-
pared with lower daily doses, and may improve treatment 
outcomes.
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